- Home
- CSBR vs PLX Comparison
CSBR vs PLX Comparison
Compare CSBR & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- PLX
- Stock Information
- Founded
- CSBR 1985
- PLX 1993
- Country
- CSBR United States
- PLX United States
- Employees
- CSBR N/A
- PLX N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CSBR Health Care
- PLX Health Care
- Exchange
- CSBR Nasdaq
- PLX Nasdaq
- Market Cap
- CSBR 123.2M
- PLX 127.4M
- IPO Year
- CSBR 1986
- PLX 1998
- Fundamental
- Price
- CSBR $6.75
- PLX $1.50
- Analyst Decision
- CSBR Strong Buy
- PLX Strong Buy
- Analyst Count
- CSBR 1
- PLX 1
- Target Price
- CSBR $12.00
- PLX $15.00
- AVG Volume (30 Days)
- CSBR 39.7K
- PLX 575.8K
- Earning Date
- CSBR 09-10-2025
- PLX 08-13-2025
- Dividend Yield
- CSBR N/A
- PLX N/A
- EPS Growth
- CSBR N/A
- PLX N/A
- EPS
- CSBR 0.33
- PLX 0.05
- Revenue
- CSBR $56,944,000.00
- PLX $59,764,000.00
- Revenue This Year
- CSBR $9.30
- PLX $10.00
- Revenue Next Year
- CSBR $31.17
- PLX $83.13
- P/E Ratio
- CSBR $19.52
- PLX $31.14
- Revenue Growth
- CSBR 13.54
- PLX 0.18
- 52 Week Low
- CSBR $3.60
- PLX $0.82
- 52 Week High
- CSBR $11.99
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CSBR 41.70
- PLX 49.35
- Support Level
- CSBR $5.85
- PLX $1.41
- Resistance Level
- CSBR $6.74
- PLX $1.53
- Average True Range (ATR)
- CSBR 0.54
- PLX 0.06
- MACD
- CSBR -0.14
- PLX 0.01
- Stochastic Oscillator
- CSBR 26.08
- PLX 39.13
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.